Abstract: The method and the apparatus are used for the low-temperature fractionation of a fluid mixture. The fluid mixture is introduced into a separation column. At least a portion of the sump liquid from the separation column is introduced into a sump evaporator and at least partly evaporated there. At least a portion of the vapor produced in the sump evaporator is led back into a lower section of the separation column. A top product is removed at the top of the separation column, and a sump product is removed from the sump of the separation column or from the sump evaporator. The sump evaporator is operated by means of inductive heating.

Abstract: The method and the apparatus are used for the low-temperature fractionation of a fluid mixture. The fluid mixture is introduced into a separation column. At least a portion of the sump liquid from the separation column is introduced into a sump evaporator and at least partly evaporated there. At least a portion of the vapor produced in the sump evaporator is led back into a lower section of the separation column. A top product is removed at the top of the separation column, and a sump product is removed from the sump of the separation column or from the sump evaporator. The sump evaporator is operated by means of inductive heating.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases.

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. These compounds may be used to modulate cellular proliferation and to prevent and/or treat proliferative diseases.

Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts, solvates, hydrates or pharmaceutically acceptable formulations thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thrombolytic conditions.

Abstract: The present invention relates to compounds of the Formula or a pharmaceutically acceptable salt, solvate, hydrate or formulation thereof. These compounds can be used for the inhibition of Factor Xa and for the treatment and/or prevention of diseases that are mediated by Factor Xa activity.

Abstract: An aqueous catalyst solution comprising rhodium and an aqueous solution comprising sulfonated arylphosphines by reacting arylphosphines with oleum to form a sulfonation mixture, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble amine in a water-insoluble organic solvent, reacting the resulting water-immiscible organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solution of sulfonated arylphosphines of pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur dioxide is no longer liberated from the aqueous solution of sulfonated arylphosphines.

Abstract: A process for preparing sulfonated arylphosphines by reaction of arylphosphines with oleum, wherein, after reaction of the arylphosphines with oleum, the sulfonation mixture is firstly diluted with water, an inert gas stream is then passed through the diluted sulfonation mixture until SO2 is no longer liberated from the diluted sulfonation mixture and the latter is then worked up further in a customary manner and its use.

Abstract: The present invention relates to new compounds of formula (I): These compounds are very effective factor VIIa inhibitors and are therefore of interest in the treatment and/or prevention of thromboses, stroke, heart attack, inflammation, arteriosclerosis and tumour conditions.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, hydrate or pharmaceutically acceptable formulation thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thromboembolic conditions.

Abstract: A process for preparing sulfonated arylphosphines by reaction of arylphosphines with oleum, wherein, after reaction of the arylphosphines with oleum, the sulfonation mixture is firstly diluted with water, an inert gas stream is then passed through the diluted sulfonation mixture until SO2 is no longer liberated from the diluted sulfonation mixture and the latter is then worked up further in a customary manner and its use.

Abstract: A process for preparing solutions of sulfonated arylphosphines comprising reacting arylphosphines with oleum, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble organic solvent, reacting the organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solutin of sulfonated arylphosphines to a pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur is no longer liberated from the aqueous solution of sulfonated arylphosphines.

Abstract: The present invention related to compounds of formula (I): or pharmaceutically acceptable salts, hydrates or pharmaceutically acceptable formulations thereof. Those compounds can be used in inhibiting factor Xa and in the prevention and/or treatment of thromboembolic conditions.

Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, hydrate or a pharmaceutically acceptable formulation thereof. Those compounds can be used for inhibiting factor Xa and for the prevention and/or treatment of thromboembolic conditions.

Abstract: The present invention relates to compounds of the Formula 1

Abstract: A process for preparing solutions of sulfonated arylphosphines comprising reacting arylphosphines with oleum, diluting the sulfonation mixture with water, extracting the diluted sulfonation mixture with a solution of a water-insoluble organic solvent, reacting the organic phase with a solution of an inorganic base in water, adjusting the resulting aqueous solutin of sulfonated arylphosphines to a pH of up to 3 by addition of an acid, and passing an inert gas stream through the aqueous solution comprising sulfonated arylphosphines until sulfur is no longer liberated from the aqueous solution of sulfonated arylphosphines.

Abstract: The invention relates to a method for producing sulfonated aryl phosphines by reacting aryl phosphines with oleum. After reacting the aryl phosphines with oleum, the sulfonation mixture is firstly diluted with water and an inert gas stream is then fed through the diluted sulfonation mixture until SO2 is no longer released from the diluted sulfonation mixture. Afterwards, the sulfonation mixture is subsequently processed in a usual manner. The invention also relates to a method for producing solutions of sulfonated aryl phosphines by reacting the aryl phosphines with oleum, diluting the sulfonation mixture with water, extracting the aqueous solution using an organic solution consisting of an amine, and subsequently carrying out a reextraction using an aqueous solution having an inorganic base.

Abstract: The present invention relates to compounds of formula (I): 1

Abstract: The present invention pertains to the object of substantially increasing the performance of an envelope-stuffing machine. While EP-A-0 504 114 discloses the use of rotating elements for opening the envelopes and for grasping the envelope flaps for this purpose, the present invention suggests that the opening and grasping of the envelopes (20) be performed in one conveying plane (13), and the introduction of the envelope contents (21) be performed in a conveying plane (12) arranged offset in relation thereto at another level, and that a link chain (10) with a plurality of spreading members (9) be provided between them, which is movable at right angles to the conveying planes (12, 13) and keeps the envelopes (20) picked up by the spreading members (9) ready at another point for the introduction of the envelope contents (21) and discharges them.